Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression‐free survival based on reconstructed individual patient data

BACKGROUND: In patients with advanced melanoma, immune‐checkpoint inhibitors (ICIs) represent the mainstay for first line treatment. Recently, relatlimab+nivolumab was proposed as a new combination therapy. This review was aimed at summarizing the current data of effectiveness for ICIs. Progression‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Ossato, Andrea, Damuzzo, Vera, Baldo, Paolo, Mengato, Daniele, Chiumente, Marco, Messori, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
REVIEWS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939083/
https://www.ncbi.nlm.nih.gov/pubmed/35920297
http://dx.doi.org/10.1002/cam4.5067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939083/
https://www.ncbi.nlm.nih.gov/pubmed/35920297
http://dx.doi.org/10.1002/cam4.5067

Ejemplares similares